Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed

被引：0
|
作者：
Meng, Xiang-Yu [1 ,2 ]
Wu, Qiu-Ji [3 ]
机构：
[1] Hubei Minzu Univ, Hlth Sci Ctr, Enshi 445000, Peoples R China
[2] Hubei Minzu Univ, Hubei Prov Key Lab Occurrence & Intervent Rheumat, Enshi 445000, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Dept Radiat & Med Oncol,Hubei Key Lab Tumour Biol, Wuhan 430071, Peoples R China
来源：
EPIGENOMICS | 2023年 / 15卷 / 22期
关键词：
biomarker; molecularly matched therapy; prognosis; targeted therapy; tumor mutation burden;
D O I：
10.2217/epi-2023-0354
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：1175 / 1178
页数：4
相关论文
共 50 条
  • [21] Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer
    Li, Yuan
    Chen, Zuhua
    Tao, Weiping
    Sun, Nan
    He, Jie
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (08) : 2367 - 2378
  • [22] Music therapy to optimise postoperative pain management: how much more evidence is needed?
    Wattar, B. H. A.
    Keay, S. D.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2020, 127 (06) : 746 - 746
  • [23] Palliative single-fraction radiation therapy: How much more evidence is needed?
    Kachnic, L
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (11): : 786 - 788
  • [24] Optimal timing of speech and language therapy for aphasia after stroke: more evidence needed
    Nouwens, Femke
    Visch-Brink, Evy G.
    Van de Sandt-Koenderman, Mieke M. E.
    Dippel, Diederik W. J.
    Koudstaal, Peter J.
    de Lau, Lonneke M. L.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (08) : 885 - 893
  • [25] Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
    Takamatsu, Shiro
    Hamanishi, Junzo
    Brown, J. B.
    Yamaguchi, Ken
    Yamanoi, Koji
    Murakami, Kosuke
    Gotoh, Osamu
    Mori, Seiichi
    Mandai, Masaki
    Matsumura, Noriomi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
  • [26] Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers.
    Offin, Michael David
    Rizvi, Hira
    Tenet, Megan
    Ni, Ai
    Vega, Francisco Sanchez
    Kris, Mark G.
    Rudin, Charles M.
    Riely, Gregory J.
    Yu, Helena Alexandra
    Hellmann, Matthew David
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Basic body awareness therapy within physiotherapy: More clarity about its' core concepts and more scientific evidence is needed
    Vancampfort, Davy
    Brunner, Emanuel
    Van Damme, Tine
    Stubbs, Brendon
    PHYSIOTHERAPY RESEARCH INTERNATIONAL, 2023, 28 (02)
  • [28] Does directly observed therapy improve tuberculosis treatment? More evidence is needed to guide tuberculosis policy
    McLaren, Zoe M.
    Milliken, Amanda A.
    Meyer, Amanda J.
    Sharp, Alana R.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [29] Does directly observed therapy improve tuberculosis treatment? More evidence is needed to guide tuberculosis policy
    Zoë M. McLaren
    Amanda A. Milliken
    Amanda J. Meyer
    Alana R. Sharp
    BMC Infectious Diseases, 16
  • [30] High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy
    Zheng, Ming
    SEMINARS IN ONCOLOGY, 2025, 52 (02)
12345